Verici Dx plc is a developer of advanced clinical diagnostics for organ transplants. The Company develops a suite of tests forming a kidney transplant platform for personalized patients and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including subclinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure.